Lancet 392:15191529 Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydn L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T (2019) REWIND Investigators

There are several good options right now: semaglutide (Wegovy), a GLP-1 receptor agonist medication tirzepatide (Zepbound), a GLP-1/GIP medication liraglutide (Saxenda), a GLP-1 medication Several oral medications are also approved by the FDA for weight loss, including: semaglutide (oral Wegovy) orforglipron (Foundayo) phentermine (Suprenza) naltrexone-bupropion (Contrave) orlistat (Xenical/Alli) These are FDA-approved for adults who have a BMI of 30 or higher or a BMI of 27 along with a weight-related condition such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, cardiovascular disease, or MASH (metabolic dysfunction-associated steatohepatitis, previously dubbed fatty liver)
Tirzepatide is administered once a week via a subcutaneous injection
Long-term safety data from extended clinical trials suggests a favorable safety profile
1,399.00 Sale price Rs
Delivers compact nutrition and include balanced Omega 3 and Omega 6 fatty acids to support development and body systems